Kura Oncology, Inc. (KURA)
NASDAQ: KURA · Real-Time Price · USD
6.02
-0.04 (-0.58%)
At close: Aug 1, 2025, 4:00 PM
6.10
+0.08 (1.41%)
After-hours: Aug 1, 2025, 5:22 PM EDT
Theseus Pharmaceuticals Employees
Kura Oncology had 192 employees as of December 31, 2024. The number of employees increased by 50 or 35.21% compared to the previous year.
Employees
192
Change (1Y)
50
Growth (1Y)
35.21%
Revenue / Employee
$354,120
Profits / Employee
-$947,328
Market Cap
521.18M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 192 | 50 | 35.21% |
Dec 31, 2023 | 142 | 9 | 6.77% |
Dec 31, 2022 | 133 | 12 | 9.92% |
Dec 31, 2021 | 121 | 32 | 35.96% |
Dec 31, 2020 | 89 | 29 | 48.33% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
KURA News
- 1 day ago - Kura Oncology to Report Second Quarter 2025 Financial Results - GlobeNewsWire
- 4 weeks ago - Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - Kura Oncology: Ziftomenib Shift Towards Newly Diagnosed Mutant AML Patients Bodes Well - Seeking Alpha
- 7 weeks ago - Kura Oncology and Kyowa Kirin Report Positive Updated Combination Data for Ziftomenib in Newly Diagnosed AML at 2025 European Hematology Association Congress - GlobeNewsWire
- 2 months ago - Kura Oncology and Kyowa Kirin Report Positive Pivotal Ziftomenib Monotherapy Data at 2025 ASCO Annual Meeting - GlobeNewsWire
- 2 months ago - Kura Oncology and Kyowa Kirin Announce FDA Acceptance and Priority Review of New Drug Application for Ziftomenib in Adults with Relapsed or Refractory NPM1-Mutant AML - GlobeNewsWire
- 2 months ago - Kura Oncology and Kyowa Kirin Announce Pivotal Monotherapy Data for Ziftomenib in Oral Presentation at the 2025 ASCO Annual Meeting - GlobeNewsWire
- 2 months ago - Kura Oncology to Participate in Three Upcoming Investor Conferences - GlobeNewsWire